Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

The market is expected to sustain range-bound trading, and the elevated volatility signals caution for bulls. Below are some ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...

HYDERABAD, India (Reuters) - India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major drugmaker Biocon Ltd said ahead of Prime Minister ...